摘要
与传统肿瘤治疗手段不同,免疫治疗是通过自身免疫系统对抗肿瘤。近几年,免疫检查点抑制剂(immune checkpoint inhibitor,ICI)疗法已被证明是一种很有前途的肿瘤免疫治疗方法,并在临床上成功地应用于多种恶性肿瘤的治疗,但确定可能受益于ICI治疗的患者仍然具有极大的挑战性。分子成像技术能实现无创实时检测,病灶和体内分布可视化,可以通过不同的放射性核素标记ICI作为示踪剂,在肿瘤的分期、疾病的动态监测和ICI治疗受益者的筛选中发挥重要作用。本述评对临床免疫检查点[程序性死亡受体1(programmed death 1,PD-1)/程序性死亡受体配体1(programmed death ligand 1,PD-L1)和细胞毒性T淋巴细胞相关抗原4(cytotoxic T lymphocyte-associated antigen-4,CTLA-4)]和新兴的免疫检查点[T细胞免疫球蛋白和黏蛋白结构域3(T cell immunoglobulin and mucin domain-containing protein 3,TIM3)和淋巴细胞活化基因3(lymphocyte activation gene-3,LAG-3)]的靶向分子成像探针进行总结,并浅析这些ICI在肿瘤治疗中的应用,同时分析免疫检查点研究中的局限,展望ICI与分子成像未来研究方向。
Different from traditional tumor treatment methods,immunotherapy is to fight tumors through the autoimmune system.In recent years,immune checkpoint inhibitors(ICI)have proven to be a promising immuno-oncology therapy method,and have been successfully applied to the treatment of many malignancies in the clinic.However,identifying patients who may benefit from ICI therapy remains extremely challenging.Molecular imaging techniques that enable non-invasive,real-time detection,visualization of lesions and in vivo distribution play an important role in tumor staging,disease dynamic monitoring,and screening of ICI treatment beneficiaries through different radionuclide-labeled ICI as tracers.This review summarized the targeted molecular imaging probes of clinical immune checkpoints[programmed death 1(PD-1)/programmed death ligand 1(PD-L1)and cytotoxic T lymphocyteassociated antigen-4(CTLA-4)]and emerging immune checkpoints[T cell immunoglobulin and mucin domain-containing protein 3(TIM3)and lymphocyte activation gene-3(LAG-3)],analyzed the application of these ICI in tumor treatment,analyzed the limitations of immune checkpoint research,and looked forward to the future research direction of ICI and molecular imaging.
作者
陶金萍
黄海峰
杨志
朱华
TAO Jinping;HUANG Haifeng;YANG Zhi;ZHU Hua(Department of Nuclear Medicine,Peking University Cancer Hospital&Institute,Key Laboratory of Carcinogenesis and Translational Research,Ministry of Education/Beijing,Key Laboratory for Research and Evaluation of Radiopharmaceuticals,National Medical Products Administration,Beijing 100142,China;School of Medicine,Guizhou University,Guiyang 550025,Guizhou Province,China;Department of Orthopedics,Guizhou Provincial People’s Hospital,Guiyang 550002,Guizhou Province,China)
出处
《肿瘤影像学》
2023年第2期122-131,共10页
Oncoradiology
基金
首都卫生发展科研专项(首发2022-2Z-2155)自主创新
贵州省科技计划项目(黔科合基础-ZK[2021]一般471)。
关键词
免疫检查点
分子成像
肿瘤
免疫治疗
抗体药物
分子探针
Immune checkpoint
Molecular imaging
Cancer
Immunotherapy
Antibody drug
Molecular probe
